Celebrex (celecoxib) after gastric sleeve surgery is a question that concerns many patients managing chronic pain or inflammatory conditions following their procedure. Sleeve gastrectomy permanently alters the stomach's anatomy, raising important questions about the safety of NSAIDs — including selective COX-2 inhibitors such as celecoxib — in the post-operative period. UK bariatric guidelines, including those from BOMSS, generally advise avoiding all NSAIDs after sleeve gastrectomy where possible, due to risks of gastric ulceration, bleeding, and cardiovascular harm. This article explains why, and outlines safer alternatives recommended within NHS clinical practice.

Why NSAIDs Are a Concern Following Bariatric Surgery

NSAIDs inhibit prostaglandin production, reducing gastric mucosal protection; after sleeve gastrectomy, the smaller gastric remnant increases vulnerability to ulceration and bleeding, so BOMSS advises avoiding NSAIDs where possible.

Non-steroidal anti-inflammatory drugs (NSAIDs) — including ibuprofen, naproxen, diclofenac, and celecoxib — are widely used for pain relief and inflammation. Following bariatric surgery, including sleeve gastrectomy, their use raises important clinical concerns that patients and clinicians should carefully consider together.

The primary concern is gastrointestinal injury. NSAIDs inhibit cyclo-oxygenase (COX) enzymes, reducing the production of prostaglandins that normally protect the stomach lining. In a post-sleeve stomach, the gastric remnant is considerably smaller, which may increase vulnerability to mucosal injury. The most well-evidenced risks include:

• Gastric ulceration, including at or near the staple line

• Gastrointestinal bleeding, which can be serious

The risk of NSAID-related gastrointestinal harm is greatest following Roux-en-Y gastric bypass, where most UK bariatric centres and the British Obesity and Metabolic Surgery Society (BOMSS) advise avoiding all NSAIDs. For sleeve gastrectomy, the guidance is similarly cautious: NSAIDs should generally be avoided where possible, and the structural changes to the stomach are permanent. If NSAID use is considered unavoidable in a post-sleeve patient, this should only be after an individual risk–benefit discussion with the bariatric team, with concurrent gastroprotection such as a proton pump inhibitor (PPI) — though this does not eliminate risk entirely.

Patients who are taking NSAIDs regularly before surgery should discuss a safe transition plan with their bariatric team well in advance of their procedure. It is also worth noting that post-bariatric patients may already have increased mucosal vulnerability due to nutritional changes, which may compound the potential for harm.

If you experience any suspected side effects from a medicine, these can be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

How Gastric Sleeve Surgery Affects Drug Absorption

Sleeve gastrectomy reduces gastric volume and accelerates emptying, but absorption of immediate-release oral medicines like celecoxib capsules is generally adequate as the small intestine remains intact.

Sleeve gastrectomy removes approximately 75–80% of the stomach, creating a narrow, tubular gastric remnant. This anatomical change has implications not only for food intake but also for how some medications are absorbed — a field known as pharmacokinetics.

Following sleeve gastrectomy, several changes may affect drug absorption in some patients:

• Reduced gastric volume means tablets and capsules pass more quickly into the small intestine

• Accelerated gastric emptying may reduce the time available for dissolution of certain formulations

• Modified-release and enteric-coated preparations may behave less predictably in the early post-operative period and are generally best avoided unless specifically reviewed

For most immediate-release oral medicines, including celecoxib capsules, absorption after sleeve gastrectomy is generally adequate, as the small intestine — where most drug absorption occurs — remains intact. This contrasts with malabsorptive procedures such as Roux-en-Y gastric bypass, which bypasses a significant portion of the upper small intestine and carries a greater risk of reduced drug absorption.

The impact of altered gastric pH on drug dissolution after sleeve gastrectomy is theoretically possible but variable and patient-specific; it is not a reliably predictable effect. Therapeutic drug monitoring is not routinely recommended or available for celecoxib, and clinical response monitoring remains the practical approach.

Patients should always inform any prescribing clinician of their surgical history. The UK Specialist Pharmacy Service (SPS) provides guidance on medicines optimisation after bariatric surgery, which pharmacists and prescribers can consult when reviewing a patient's medication regimen.

Celecoxib After Gastric Sleeve: What UK Guidelines Advise

UK bariatric guidelines and BOMSS advise against celecoxib and all NSAIDs post-sleeve gastrectomy where avoidable; if use is essential, a full risk–benefit discussion with the bariatric and specialist team is required alongside PPI cover.

Celecoxib (brand name Celebrex; other brands are available) is a selective COX-2 inhibitor, meaning it preferentially blocks the COX-2 enzyme rather than COX-1. Because COX-1 plays a key role in maintaining the protective gastric mucosa, selective COX-2 inhibitors were developed to carry a lower risk of gastrointestinal side effects compared to traditional non-selective NSAIDs such as ibuprofen or naproxen.

However, celecoxib is not free of gastrointestinal risk. The Summary of Product Characteristics (SmPC) for celecoxib and MHRA guidance both identify gastrointestinal ulceration and bleeding as recognised adverse effects, particularly in patients with pre-existing risk factors. Importantly, celecoxib also carries cardiovascular and renal risks that must be considered:

• Cardiovascular risk: COX-2 inhibitors, including celecoxib, are associated with a small but increased risk of serious cardiovascular events (such as myocardial infarction and stroke), particularly with higher doses and prolonged use. The MHRA has issued Drug Safety Updates on this topic.

• Renal risk: NSAIDs including celecoxib can impair renal function, cause fluid retention, and worsen hypertension.

For these reasons, the SmPC and MHRA advise using celecoxib at the lowest effective dose for the shortest duration necessary.

In the context of post-sleeve gastrectomy, BOMSS guidance and most UK bariatric centres advise against the use of all NSAIDs, including selective COX-2 inhibitors such as celecoxib, where this can be avoided. There is no specific NICE technology appraisal addressing celecoxib use post-bariatric surgery, but clinical consensus supports a cautious approach given the altered gastric anatomy.

If a patient has a condition (such as inflammatory arthritis) that has historically been managed with celecoxib, this should be reviewed by both their rheumatologist and bariatric team before and after surgery. Any decision to use celecoxib post-sleeve should involve a full risk–benefit discussion, awareness of gastrointestinal, cardiovascular, and renal risks, and ideally concurrent PPI gastroprotection. NICE Clinical Knowledge Summaries (CKS) on NSAIDs — prescribing issues provide further guidance on minimising risk.

Safer Pain Relief Alternatives Recommended Post-Surgery

Paracetamol is the first-line analgesic after sleeve gastrectomy; topical NSAIDs, physiotherapy, neuropathic agents, and intra-articular injections are preferred alternatives to oral NSAIDs for ongoing pain.

Given the concerns surrounding NSAID use after sleeve gastrectomy, patients and clinicians should be aware of safer analgesic alternatives for both acute and chronic pain management following bariatric surgery.

Paracetamol remains the first-line analgesic of choice post-bariatric surgery. It is generally well tolerated, does not carry the gastrointestinal risks associated with NSAIDs, and is available in multiple formulations. Soluble or liquid preparations may be preferable in the early post-operative period.

For more significant pain, the following options may be considered under medical supervision:

• Weak opioids (e.g., codeine or tramadol) may be used for short-term acute pain, but carry risks including constipation (a laxative should be co-prescribed), sedation, and dependency. Patients should be aware of impaired driving ability. In line with NICE guideline NG193 (Chronic pain: assessment and management), opioids — including tramadol — are not recommended for chronic primary pain and should not be initiated or continued long-term without specialist review and a clear plan for deprescribing.

• Topical NSAIDs (e.g., diclofenac gel) may be appropriate for localised musculoskeletal pain. Systemic absorption is considerably lower than with oral NSAIDs, but is not negligible; topical NSAIDs should be applied to small areas for the shortest time necessary, and patients should discuss use with their GP. NICE guideline NG226 (Osteoarthritis: diagnosis and management) supports topical NSAIDs as a first-line option for joint pain where appropriate.

• Physiotherapy and non-pharmacological approaches, including exercise therapy, hydrotherapy, and psychological support such as cognitive behavioural therapy (CBT), are recommended for chronic pain conditions and align with NICE NG193.

• Neuropathic agents such as amitriptyline, duloxetine, or gabapentin may be appropriate for nerve-related pain under specialist guidance, in line with NICE guideline CG173 (Neuropathic pain in adults). These medicines require careful titration and monitoring for adverse effects.

• Intra-articular corticosteroid injections for joint-specific inflammation, administered by a rheumatologist or musculoskeletal specialist, can provide targeted relief without systemic NSAID exposure.

The goal should always be to use the lowest effective dose of the safest available agent, with regular review. Patients should not self-medicate with over-the-counter NSAIDs without first consulting their GP or bariatric team.

Talking to Your Bariatric Team About Long-Term Pain Management

Patients should discuss all pain medications with their bariatric MDT before and after surgery; urgent symptoms such as vomiting blood, black stools, or severe abdominal pain require immediate emergency care via 999 or A&E.

Not sure if this is normal? Chat with one of our pharmacists →

Open communication with your bariatric multidisciplinary team (MDT) is essential — both before and after surgery — particularly if you have a pre-existing condition requiring regular pain relief or anti-inflammatory medication. Many patients are unaware that common over-the-counter medicines such as ibuprofen are generally contraindicated following sleeve gastrectomy, and this knowledge gap can lead to inadvertent harm.

Before your surgery, your bariatric team should conduct a comprehensive medication review. If you are currently taking celecoxib or any other NSAID for a chronic condition, this is the time to discuss alternatives. Your GP, rheumatologist, or pain specialist may need to be involved in developing a safe long-term plan.

After surgery, if you experience new or worsening pain — whether musculoskeletal, abdominal, or otherwise — do not self-treat with NSAIDs or celecoxib. Instead:

• Contact your GP for advice on appropriate analgesia

• Call NHS 111 if you need urgent medical advice and your GP is not available

• Call 999 or go to A&E immediately if you experience any of the following, as these may indicate serious gastrointestinal bleeding or another surgical emergency:

• Vomiting blood or material that looks like coffee grounds
• Black, tarry, or bloody stools
• Severe or sudden abdominal or epigastric pain
• Fainting, collapse, or persistent rapid heartbeat

• Fever with worsening abdominal pain

• Inform all prescribers — including your GP, dentist, and any emergency clinician — of your surgical history before accepting any new medication. Carrying a bariatric surgery information card or letter can help ensure this information is communicated promptly.

Long-term pain management after bariatric surgery is a specialist area, and many NHS bariatric centres offer ongoing follow-up clinics where these issues can be addressed. If pain is significantly affecting your quality of life, ask for a referral to a pain management clinic or relevant specialist. With the right support, effective and safe pain control is achievable without resorting to medicines that carry unacceptable risks in the post-sleeve setting.

If you experience a suspected side effect from any medicine, please report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or using the Yellow Card app.

Experiencing these side effects? Our pharmacists can help you navigate them →

Frequently Asked Questions